Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)
- The report reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics and enlists all their major and minor projects
- The report assesses Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Activate Therapeutics LLCAiViva BioPharma Inc
Amgen Inc
Aresus Pharma GmbH
Ascend Biopharmaceuticals Ltd
Bayer AG
Biocidium Biopharmaceuticals Inc
Biofrontera AG
Biomed
Bristol-Myers Squibb Co
Coegin Pharma AB
Enkang Pharmaceutical Technology (Guangzhou) Co Ltd
Evotec SE
Feldan Therapeutics Inc
Genentech USA Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
IMVAQ Therapeutics Corp
Ingenew Pharmaceuticals Inc
Institute of Oncology Ljubljana
Invion Ltd
IO Biotech Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
Laboratories Ojer Pharma SL
Leo Pharma AS
Mayne Pharma Group Ltd
MedC Biopharma Ltd
Medicenna Therapeutics Corp
Medivir AB
MediWound Ltd
Merck & Co Inc
Moderna Inc
Morphogenesis Inc
Multitude therapeutics Inc
Mustafa Nevzat Ilac ve Kimyevi Maddeler San Tic AS
Neonc Technologies Inc
NuCana Plc
Ono Pharmaceutical Co Ltd
Palvella Therapeutics LLC
Philogen SpA
Promontory Therapeutics Inc
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Singh Biotechnology LLC
Sirnaomics Ltd
Sol-Gel Technologies Ltd
Turn Therapeutics Inc
Varian Biopharmaceuticals Inc
Verrica Pharmaceuticals Inc
Xencor Inc